此外,Axcynsis的AxcynDOT技术也为其他类型的肿瘤治疗提供了潜在的解决方案,进一步推动了癌症治疗的创新发展。 展望未来 技术应用前景 Axcynsis的AxcynDOT技术不仅在AT03-65中展现了其巨大潜力,未来也有望在其他类型的肿瘤治疗中发挥作用。随着技术的不断进步和临床试验的成功,Axcynsis有望在全球范围内推广其创新药物...
泰诚思生物创始人兼首席执行官邹斌博士表示: “This is a transformational event for Axcynsis and a significant milestone for our proprietary ADC platform using AxcynDOT™,” said Dr. Zou Bin, CEO of Axcynsis. “We are pleased that FDA has cleared AT03-65 which leverages our AxcynDOT™ ...
We are very excited with the potential of offering a transformative therapeutic option for patients with CLDN6-positive tumors as well as advancing our pipeline with differentiated and effective ADCs using AxcynDOT™ to im...
AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development
Axcynsis Therapeutics是一家总部位于新加坡的生物科技公司,专注于开发靶向癌症的治疗方法。AT03-65是其最新的创新药物,利用了公司独特的AxcynDOT技术,将抗体药物结合到CLDN6蛋白质上,从而精确地攻击癌细胞。 核心数据 AT03-65的关键特点 靶点:CLDN6蛋白质 ...